Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALS Untangled No. 20: the Deanna protocol.
ALSUntangled Group; Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E. ALSUntangled Group, et al. Among authors: pattee g. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23638638 Review. No abstract available.
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Genge A, Pattee GL, Sobue G, Aoki M, Yoshino H, Couratier P, Lunetta C, Petri S, Selness D, Bidani S, Hirai M, Sakata T, Salah A, Apple S, Wamil A, Kalin A, Jackson CE. Genge A, et al. Among authors: pattee gl. Muscle Nerve. 2023 Feb;67(2):124-129. doi: 10.1002/mus.27768. Epub 2022 Dec 28. Muscle Nerve. 2023. PMID: 36504406 Free PMC article. Clinical Trial.
Creatine and coenzyme Q10 in the treatment of ALS.
Strong MJ, Pattee GL. Strong MJ, et al. Among authors: pattee gl. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1 Suppl 4:17-20. doi: 10.1080/14660820050515665. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000. PMID: 11466954 Review. No abstract available.
ALSUntangled update 4: investigating the XCell-Center.
ALSUntangled Group. ALSUntangled Group. Amyotroph Lateral Scler. 2010 May 3;11(3):337-8. doi: 10.3109/17482961003755005. Amyotroph Lateral Scler. 2010. PMID: 20443222 No abstract available.
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Pioro EP, et al. Ann Neurol. 2010 Nov;68(5):693-702. doi: 10.1002/ana.22093. Ann Neurol. 2010. PMID: 20839238 Clinical Trial.
Peer recommendations on how to improve clinical research, and Conference wrap-up.
Chad DA, Rowland LP, Armon C, Bedlack R, Durham H, Factor-Litvak P, Heiman-Patterson T, Heitzman D, Lacomis D, Ludolph A, Maragakis N, Miller R, Pattee G, Shoesmith C, Sorenson E, Turner MR. Chad DA, et al. Among authors: pattee g. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:67-73. doi: 10.3109/21678421.2013.778605. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23678882
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Cudkowicz ME, et al. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Lancet Neurol. 2013. PMID: 24067398 Clinical Trial.
108 results